Procalcitonin-guided antibiotic therapy for septic patients in the surgical intensive care unit by unknown
Carr Journal of Intensive Care  (2015) 3:36 
DOI 10.1186/s40560-015-0100-9REVIEW Open AccessProcalcitonin-guided antibiotic therapy for
septic patients in the surgical intensive care
unit
John Alfred CarrAbstract
In critically ill patients, elucidating those patients with the systemic inflammatory response syndrome (SIRS) from an infectious
source (sepsis), versus those who have SIRS without infection, can be challenging since the clinical features are the same.
Even with strict monitoring and testing, 39–98 % of patients with SIRS will never have bacteriological confirmation of
an infection, and 6–17 % of patients with a documented infection will not show signs of SIRS. Due to this overlap, an
extensive amount of research has been performed to investigate ways of determining and separating SIRS from
infection, compared to SIRS due to trauma, surgical stress, or other non-infectious causes. This review article will discuss
the recommended and peer-approved use of procalcitonin in septic patients in the intensive care unit and its use as a
guide to antibiotic initiation and termination. The article will focus on the prospective randomized trials (Level 1 evidence)
that have been conducted, and lesser levels of evidence will be referenced as needed to substantiate a conclusion.
The literature documents multiple benefits of using procalcitonin as a guide to cost savings and appropriate termination
of antibiotics by its use as a new objective marker of bacteremia that was previously not available. This article will show
that antibiotics should be terminated when the procalcitonin level falls below 0.5 ng/mL.Introduction
In critically ill patients, elucidating those patients with
the systemic inflammatory response syndrome (SIRS)
from an infectious source (sepsis), versus those who
have SIRS without infection, can be challenging since
the clinical features are similar [1, 2]. Even with strict
monitoring and testing, 39–98 % of patients with SIRS
will never have bacteriological confirmation of an infec-
tion, and 6–17 % of patients with a documented infec-
tion will not show signs of SIRS [3]. Due to this
overlap, an extensive amount of research has been per-
formed to investigate ways of determining and separat-
ing SIRS from infection, compared to SIRS due to
trauma, surgical stress, or other non-infectious causes.
The impetus behind this research is founded, since
the mortality rate for patients in septic shock increases
by 7 % per hour within the first 6 h of delayed anti-
biotic administration [4]. And those patients with sepsis
from ventilator-associated pneumonia who had a delay
of more than 24 h after diagnosis until initiation of
antibiotics had a sevenfold higher mortality rateCorrespondence: heartandbones@yahoo.com
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[5]. Thus, it is paramount that patients developing SIRS
are quickly screened to ensure an underlying infectious
process is not overlooked. The Surviving Sepsis Cam-
paign recommends blood cultures and “imaging studies
performed promptly” as screening tools to determine
the infectious source [6]. However, blood cultures
require days in order to obtain results, and imaging
studies are not comprehensive in ruling out an infec-
tious source. This has led to the search for an appropri-
ate serum biomarker to determine and differentiate
sepsis from SIRS.
Extensive research looking for the right serum bio-
marker has covered many potential candidate markers,
but the most extensively researched have been
interleukin-6, interleukin-8, interleukin-10, C-reactive
protein (CRP), and procalcitonin [7–9]. Most of this re-
search has concluded that IL-6, IL-8, IL-10, and CRP
are non-specific in separating SIRS due to infection from
non-infectious SIRS. However, procalcitonin levels are
only mildly elevated in SIRS but become significantly
elevated in sepsis and dramatically elevated with Gram-
negative sepsis [10, 11]. This finding, although initiallytributed under the terms of the Creative Commons Attribution License (http://
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under-utilized in the care of septic patients until recently,
when the research in this area has greatly improved [12].
This review article will discuss the recommended and
peer-approved use of procalcitonin in septic patients in
the intensive care unit (ICU) and its use as a guide to
antibiotic initiation and termination. Due to the volu-
minous research on procalcitonin and in order to draw
appropriate conclusions from the data, this review
article will focus only on the use of procalcitonin in
septic patients in an ICU setting. Since the procalcito-
nin level is much higher in septic patients than those with
an isolated pulmonary infection, results from these over-
lapping studies (pulmonary infection without sepsis, pul-
monary infection with sepsis, and non-pulmonary sepsis)
will be addressed and compared to substantiate the cutoff
levels of procalcitonin and its appropriate use as a bio-
marker of sepsis. The article will focus on the prospective
randomized trials (Level 1 evidence) that have been con-
ducted, and lesser levels of evidence will be referenced as
needed to substantiate a conclusion.
The literature documents multiple benefits of using
procalcitonin as a guide to cost savings and appropriate
termination of antibiotics by its use as a new objective
marker of bacteremia that was previously not available.
This article will show that previous “standard” courses
of treatment based upon a pre-set number of 10, 14, or
21 days are no longer appropriate in septic patients and
that antibiotics should be terminated when the procal-
citonin level falls below 0.5 ng/mL.
Review
Molecular physiology
Procalcitonin is the prohormone of calcitonin, but un-
like calcitonin which is induced by hypercalcemia, pro-
calcitonin is induced by the activation and adherence of
monocytes to the endothelial layer of blood vessels as
occurs during sepsis [13, 14]. Unlike cytokines, which
can rise and fall due to multiple overlapping and miti-
gating physiological interactions, procalcitonin release
is more tightly controlled and only found in the sys-
temic circulation during response to severe stress and
sepsis [14–16]. Multiple research studies have com-
pared procalcitonin to C-reactive protein, cytokines
(IL-6, IL-8, IL-10), and lactate, and all of these studies
(except one, ref. [17]) have found that procalcitonin
was much more sensitive and specific in accurately
diagnosing sepsis, and the resolution of sepsis, than any
of the other markers [1, 2, 7–9, 12, 18, 19]. In addition,
it is useful that procalcitonin levels in normal individ-
uals are very low (<0.1 ng/mL) [14]. Thus, there is sub-
stantial evidence that procalcitonin is a reliable marker
of sepsis and certainly the best of the biomarkers yet to
be identified.Prospective randomized trial results
Having established that procalcitonin is a marker of sepsis,
the basic science research was supported and upheld by
nine prospective randomized trials and refuted by one
prospective randomized trial (Tables 1 and 2) [20–29].
Thus, there have been a total of ten prospective ran-
domized trials, and nine have published results (refs.
[20–27, 29]), and the tenth trial has closed, but the re-
sults have not yet been published at the time of this
writing (ref. [28]). It is important to note that not all of
the trials were performed in the same patient popula-
tions, and therefore, the studies will be grouped and
discussed by the population they examined.
Pneumonia and respiratory infection
Three of the trials enrolled patients with acute respiratory
infections or community-acquired pneumonia [20, 23, 26].
One enrolled only patients with ventilator-associated
pneumonia and will be discussed separately [25]. These
four studies represent pulmonary infection without sepsis.
These trials are an important comparative group (without
sepsis) to examine against the trials that studied procalci-
tonin in septic patients.
In all of these trials, an algorithm was followed to
determine the initiation and duration of antibiotic ther-
apy based upon serial procalcitonin levels and discon-
tinuation of antibiotics when the procalcitonin level
dropped below a pre-determined cutoff level. The three
studies examining the use of procalcitonin in guiding
therapy for acute respiratory infections and community-
acquired pneumonia all reported similar conclusions. All
three studies used the same cutoff level of 0.25 μg/L or
less as the point to stop antibiotics. And all three con-
cluded that procalcitonin reduced total antibiotic expos-
ure, reduced antibiotic treatment duration, and created
similar treatment success in experimental and control
groups, and no increased risk was found in stopping the
antibiotics once the procalcitonin level normalized. Two
of the three also showed that the procalcitonin level was
effective in preventing the initial use of antibiotics when
the level was initially normal (<0.25 μg/L) [20, 23].
These studies showed a median decrease in antibiotic
treatment duration of 7, 1, and 3 days, respectively.
In the one trial studying exclusively those patients with
ventilator-associated pneumonia (VAP), the inclusion
criteria for diagnosis and the standard treatment of VAP
were based upon the previously published guidelines
[30]. The procalcitonin cutoff level to stop antibiotics
was slightly higher than in the other trials at 0.5 μg/L or
less [25]. The authors concluded that procalcitonin
allowed a reduction in the overall duration of antibiotic
therapy and overall patient exposure to antibiotics. The
median decrease in antibiotic treatment was 5 days in
the procalcitonin group. The rate of discontinuation of
Table 1 Results of prospective randomized trials
Country Author Ref Trial name Year Number Population PCT E PCT C Number of fewer days of antibiotic use
Use in respiratory infections
Switzerland Christ-Crain [20] None 2006 302 CAP 0.57 0.44 Yes, 7 days
Switzerland Briel [23] None 2008 458 resp infect 0.8 0.8 Yes, 1 day
Swiss/USA Stolz [25] None 2009 101 VAP 0.6 0.7 Yes, 5 days
Switzerland Schuetz [26] ProHosp 2009 1359 resp infect 0.24 0.24 Yes, 3 days
Use in sepsis
Switzerland Nobre [21] None 2008 79 Sepsis 8.4 5.9 Yes, 3.5 days
Germany Schroeder [22] None 2008 27 Severe sepsis 7.0 6.0 Yes, 1.7 days
Sepsis in the ICU setting
Germany Hochreiter [24] None 2009 110 SICU 4.5 4.8 Yes, 2 days
France Bouadma [27] PRORATA 2010 621 ICU 12.0 12.0 Yes, 3 days
Netherlands De Jong [28] SAPS 2013 1816 ICU – – Results pending
Australia Shehabi [30] ProGuard 2014 400 ICU 5.7 8.8 No, 2 days not statistically significant
Ref reference number, n number of patients enrolled in the study, CAP community-acquired pneumonia, resp infect respiratory infection, SICU surgical intensive
care unit, VAP ventilator-associated pneumonia, ICU intensive care unit, PCT E initial procalcitonin level in the experimental group (ng/mL), PCT C initial procalcitonin level
in the control group (ng/mL)
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group. The groups had a similar number of mechanical
ventilation days and ICU days. Morbidity and mortality
levels were also similar. No increased risk of adverse
events was found by discontinuing antibiotics using the
procalcitonin-guided algorithm.
Sepsis in the ICU setting
Four of the prospective randomized trials focused on
septic patients (from any source) in an ICU setting, and
these trials will be considered together [21, 22, 24, 27].
In all four trials, an algorithm was followed using procal-
citonin to guide the duration of antibiotic therapy and to
continue antibiotic therapy based upon serially elevatedTable 2 Results of prospective randomized trials
Country Author Ref Trial name Year Conclusions
Use in respiratory infections
Switzerland Christ-Crain [20] None 2006 PCT level prev
Switzerland Briel [23] None 2008 PCT level prev
Swiss/USA Stolz [25] None 2009 PCT level allow
Switzerland Schuetz [26] ProHosp 2009 adverse outco
Use in sepsis
Switzerland Nobre [21] None 2008 PCT allowed e
Germany Schroeder [22] None 2008 PCT allowed e
Use in sepsis in the ICU setting
Germany Hochreiter [24] None 2009 PCT allowed e
France Bouadma [27] PRORATA 2010 PCT allowed e
Netherlands De Jong [28] SAPS 2013 No longer rec
Australia Shehabi [30] ProGuard 2014 PCT group ha
Ref references, PCT procalcitonin, antibx antibioticsprocalcitonin levels until the procalcitonin level dropped
below a pre-determined value. At that point, antibiotics
were discontinued. Both the procalcitonin group and the
control group had a baseline procalcitonin level mea-
sured upon initial presentation and inclusion into the
study, but only the experimental group had serial procal-
citonin levels checked to guide treatment. The control
groups were treated by standard courses of antibiotics
until the patient was clinically determined to have re-
solved their septic process.
In all four trials, sepsis was defined appropriately and
documented with the Simplified Acute Physiology Score
(SAPS II) and the Sequential Organ Failure Assessment
(SOFA) score. The rates of microbiologically confirmedented initial antibx use, earlier discontinuation antibx, less overall use
ented initial antibx use, decreased overall antibx exposure and duration
ed earlier discontinuation antibx, decreased total exposure and duration
mes similar, PCT group had fewer adverse events, less total antibx use
arlier discontinuation of antibx, decreased overall antibx exposure
arlier discontinuation of antibx, cost of antibx reduced
arlier discontinuation of antibx, shorter ICU length of stay
arlier discontinuation of antibx, decreased overall antibx exposure
ruiting patients, results pending
d 2 less days of antibx but not statistically significant
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procalcitonin-guided and control groups. The median
procalcitonin levels on admission to the ICU were similar
between the groups and are listed in Table 1.
However, the initial procalcitonin levels are all signifi-
cantly higher in the sepsis trials and the sepsis-in-the-ICU-
setting trials, compared to the respiratory infection/pneu-
monia trials (Table 1). The procalcitonin levels in the
sepsis-ICU-setting trials ranged from 4.5 to 12.0 ng/mL
compared to 0.24–0.8 μg/L in the respiratory infection/
pneumonia patients. Clearly, the septic patients in the ICU
setting were more toxic, and this is reflected in the higher
procalcitonin levels. While some authors report procalcito-
nin levels in microgram per liter (μg/L) and some report
the levels in nanogram per milliliter (ng/mL), the reader
should be aware that these are, in fact, the same amount,
i.e., 1 ng/mL equals 1 μg/L.
The procalcitonin cutoff level for discontinuation of
antibiotics was different in all of the ICU-setting trials.
In two trials, the cutoff level for discontinuation of anti-
biotics was <1 ng/mL or less than 35 % of the initial
value within 3 days [22, 24]. This level was similar in the
two studies because the Schroeder study [22] appears to
be a subgroup analysis of the same patients during the
same time period by the same authors as the Hochreiter
study [24].
In the other two trials, the cutoff level for discontinu-
ation of antibiotics was <0.25 μg/L or a drop of more
than 90 % of the peak level in one trial and <0.5 μg/L or
a drop of more than 80 % of the peak concentration in
the other [21, 27]. What the appropriate cutoff level
should be will be discussed later in the manuscript.
Despite the differences in what value would determine
discontinuation of antibiotics, all four trials drew similar
conclusions. In all studies, the duration of antibiotic treat-
ment was significantly shorter in the procalcitonin-guided
groups. The median reduction in antibiotic treatment days
was 3.5, 1, 2, and 3 days, respectively [21, 22, 24, 27].
Overall antibiotic exposure was also less in the
procalcitonin-guided patients. And none of the trials
showed an increase in adverse events or treatment failure
rates due to fewer antibiotic days. The Schroeder study
also concluded procalcitonin significantly reduced the cost
of antibiotics by 18 %, and the Nobre trial showed a statis-
tically significant shorter ICU length of stay [21, 22]. Cure
rates, morbidity, and mortality rates were similar between
the groups in all of the trials.
One significant concern with a procalcitonin-guided
algorithm to stop antibiotics is that a persistently septic
patient will have antibiotics discontinued prematurely,
resulting in recurrence of infection or other sepsis-
related morbidity. This issue was addressed in two of the
trials [21, 27], and their secondary endpoints are worth
noting in terms of recurrence of infection. The Nobretrial showed that in those patients with a positive blood
culture who were assigned to the procalcitonin arm and
received a shorter course of antibiotics, no case of recur-
rent infection was observed after the procalcitonin level
had dropped below the cutoff level (0.25 μg/L) [21].
Similarly, in the PRORATA trial, in the procalcitonin-
guided arm, no deaths were recorded as related to re-
lapse of infection after discontinuation of antibiotics
(cutoff level 0.5 μg/L) [27].
In the PRORATA trial, 28 patients with clinical signs of
SIRS assigned to the procalcitonin arm, and 15 patients
assigned to the control arm, had initial levels <0.5 ng/mL
and were therefore not treated with antibiotics at inclusion
into the study. Of the 28 in the procalcitonin arm, eight pa-
tients showed a subsequent increase in their procalcitonin
level and were later given antibiotics by day 5 (20 patients
were never given antibiotics), and there was one death on
hospital day 18 from comorbidities. The remainder of the
patients did well. Of the 15 patients in the control arm not
given antibiotics at inclusion and not having serial procalci-
tonin levels checked, eight patients were later treated with
antibiotics (within 5 days due to clinical deterioration) and
four died. The authors concluded that, in terms of mortal-
ity, the procalcitonin arm was non-inferior to the control
group [27].
Unlike the four prospective randomized trials in a
sepsis-ICU-setting mentioned above, there was one pro-
spective randomized trial performed in ICUs in Australia
which had negative results [29]. Called the ProGuard
trial, this trial was different from the other four ICU-
setting trials because the procalcitonin cutoff level to
stop antibiotics was set very low at 0.1 ng/mL. This is a
normal value [14]. The authors found that with a cutoff
level of 0.1 ng/mL, the procalcitonin group did have a
median of 2 less days of antibiotics, but this was not sig-
nificant (p = 0.58) [29]. The authors concluded that a
procalcitonin algorithm using a 0.1 ng/mL cutoff does
not achieve a significant (>25 %) reduction in antibiotic
duration.
Determining the appropriate level to discontinue
antibiotics
As the ProGuard trial proved, finding the appropriate
cutoff value to stop antibiotics is the yet-to-be-deter-
mined critical piece of information that is currently un-
known. The Nobre trial showed that a cutoff level of
0.25 μg/L was safe to stop antibiotics, since no recurrent
infections were reported after stopping antibiotics at that
level [21]. However, a higher cutoff level of 0.5 μg/L was
also shown to be safe, with no recurrent infections re-
ported at that level, and that level also allowed a signifi-
cant reduction in antibiotic usage [27]. With the cutoff
level sets too low at 0.1 ng/mL, as in the ProGuard trial,
no significant benefit was observed.
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randomized trials combined, the appropriate cutoff level
to stop antibiotics in septic patients in an ICU setting
appears to be a serum concentration of procalcitonin of
<0.5 ng/mL. This number was successfully used as the
cutoff level to stop antibiotics in two of the prospective
trials [25, 27], and two trials that used an even higher
level of 1.0 ng/mL also reported successful outcomes,
although this level is not as frequently cited, and consid-
ered too high by other researchers [22, 24]. The 0.5 ng/
mL level was also successfully used as an initial thresh-
old not to start antibiotics upon enrollment in three
trials [25–27]. With antibiotics withheld at this range,
the patients still had successful outcomes.
In order to add more support to using a level <0.5 ng/
mL as the cutoff level to stop antibiotics in septic ICU pa-
tients, it is helpful to also outline what the literature shows
as regards the procalcitonin level that becomes diagnostic,
or at least more indicative, of sepsis. The cutoff level toTable 3 Procalcitonin diagnostic levels for sepsis in prospective stud
Name Year Number Ref PCT <0.5 0.6 to <1.
Al-Nawas 1996 337 [32] 0.5
Bossink 1999 200 [33] 0.5
Sudhir 2011 100 [34] 0.5
Ugarte 1999 205 [35] 0.6
Muller 2000 101 [36] 1.0
Aouifi 2000 97 [37] 1.0
Ruokonen 2002 208 [38] 0.8
G-B 2002 119 [39] 1.0
Whang 1998 29 [40]
Oberhoffer 2000 242 [41]
Wanner 2000 405 [42]
Harbarth 2001 78 [9]
Tugrul 2002 85 [43]
Hensler 2003 137 [44]
Castelli 2004 150 [18]
Mokart 2005 50 [45]
Brunkhorst 2000 185 [46]
Suprin 2000 101 [47]
Meisner 2002 208 [48]
DeTalance 2003 108 [49]
Luzzani 2003 70 [50]
Du 2003 51 [51]
Geppert 2003 55 [52]
Endo 2008 82 [53]
Meynaar 2011 76 [54]
aThese studies included trauma patients, PCT is known to rise after trauma unrelate
ref referencestop antibiotics needs to be well below the diagnostic level
at which sepsis is confirmed.
The procalcitonin level diagnostic of sepsis
In addition to the prospective randomized trials already
discussed, there have been an additional 25 prospective
non-randomized studies investigating the appropriate
level of procalcitonin that is diagnostic of sepsis in ICU
patients [9, 18, 31–53]. Since the procalcitonin level has
been shown to be consistently higher in septic patients,
than those with only bacteremia, respiratory infections,
or pneumonia, the ability to find an appropriate diagnos-
tic range is enhanced in this population. And therefore,
the results of those studies that focused on patients in
the emergency department setting, medical wards, and
outpatients have been excluded.
The results of those studies that investigated the procalci-
tonin level diagnostic of sepsis in ICU populations are
shown in Table 3 with the procalcitonin levels separated inies in ICU populations



























Table 4 Content and references
Subject References
Prospective randomized trials [20–28, 30]
Discontinuing antibiotics [20–28]
Diagnosing sepsis [9, 18, 32–54]
Differentiating sepsis and SIRS [10, 18, 20–24, 26, 27, 30, 55–57]
Monitoring sepsis [16, 17, 19, 31, 58–61]
Carr Journal of Intensive Care  (2015) 3:36 Page 6 of 8groups of ≤0.5, 0.6 to ≤1.0, 1.1 to ≤1.5, and 1.6 to 2.0. The
highest sensitivities to detect sepsis were found in those
studies that made the diagnosis of sepsis based upon a pro-
calcitonin range of 2.0 ng/mL or higher [45–49, 51–53]. In
these studies, the sensitivity to detect sepsis ranged from
65 to 96 %, although six of the studies found the sensitivity
to be greater than 86 % [45, 47, 48, 51–53]. In those same
studies, the specificity ranged from 70 to 89 % [45–49, 51–
53]. As one would expect, as the diagnostic level is
dropped down to 1.5 ng/mL or 1.0 ng/mL or less, the over-
all sensitivity drops as well (Tables 3 and 4) [9, 18, 31–44].
With this in mind, another review of Table 1 display-
ing the five prospective randomized trials in septic pa-
tients that were conducted in an ICU setting shows that
the initial procalcitonin level documented for the septic
patients in those trials ranged from 4.5 to 12 ng/mL.
Thus, the diagnostic level of 2.0 ng/mL appears to be
appropriate to diagnose sepsis in an ICU population,
with an acceptable sensitivity and specificity.
Differentiating sepsis from SIRS
The third piece of information to be discussed is differ-
entiating sepsis from SIRS. Although there is significant
evidence supporting elevated procalcitonin in septic pa-
tients, procalcitonin levels are also mildly elevated in
SIRS without infection. Several studies have addressed
areas of overlap between the two.
It has been documented from the outpatient versus
ICU-setting trials that the initial level of procalcitonin
will be higher in a patient with sepsis compared to one
with only a respiratory infection or bacteremia (Table 1).
In addition, procalcitonin is not elevated in patients with
a simple localized infection. While the three outpatient
prospective randomized trials examining the usefulness
of procalcitonin in respiratory infections did show true
benefit, the procalcitonin levels were not highly elevated,
and the differences between starting levels, peak levels,
and the cutoff levels were quite small [20, 23, 26].
This is because every patient with an infection is not
septic, and procalcitonin has shown its real value in
determining when to stop antibiotics in septic patients
in an ICU setting. All of the prospective randomized
ICU trials showed significant elevations in the procalci-
tonin levels in septic patients [21, 22, 24, 27, 29]. Two
observational studies that examined the differences inprocalcitonin levels in patients with documented sepsis
compared to SIRS found that the median level in septic
patients ranged from 1.58 to 29.3 ng/mL, while in the
SIRS group, the median levels were 0.38–0.74 ng/mL
[10, 18]. Another study that examined baseline procalci-
tonin levels in patients with end-stage renal disease on
hemodialysis without infection found that as their base-
line inflammatory state reflects, the procalcitonin levels
in these patients remained mildly chronically elevated at
a median range of 0.50 ± 0.49 ng/mL [54]. A study that
investigated the procalcitonin levels in patients with
neurotrauma without infection found that, depending
upon the severity of the brain injury, the procalcitonin
levels were mildly elevated from 0.05 to 0.13 for mild
brain injury, 0.11 to 0.55 for moderate injury, and 0.17 to
0.79 for severe brain injury [55]. Overall, these studies
have concluded that most patients with non-infectious
SIRS maintain an inflammatory-mediated procalcitonin
level from 0.3 to 0.8 ng/mL [10, 18, 54–56].
Using procalcitonin to monitor for sepsis in the ICU: static
levels versus trends
Although older research showed that procalcitonin levels
in sepsis do not correlate with mortality [17], more re-
cent work has shown that increased mortality was docu-
mented for patients with pneumonia whose levels
exceed 2.5 ng/mL and in septic trauma patients whose
levels exceed 5 ng/mL [19, 57]. In addition, a persistent
elevation in the procalcitonin level, or no decrease in the
level after antibiotic treatment, has been shown to cor-
relate with a higher mortality rate [58–61].
Thus, it is important to continue to follow the trend of
the procalcitonin level while the patient is in the ICU.
The level can change, and certainly, a patient initially ad-
mitted to the ICU may subsequently develop an infec-
tion, or later become septic, and the procalcitonin is a
useful guide to follow. A dramatic increase in the procal-
citonin level should certainly raise suspicion of an infec-
tion or worsening of an ongoing septic process. It has
been recommended that if the clinical picture is indica-
tive of sepsis, and the initial procalcitonin level is low,
that antibiotics should be started anyway, and repeat
procalcitonin levels checked at 12, 24, and 36 h until the
diagnosis is clear [16].
Having now established that a level ≥2.0 ng/mL is most
sensitive and specific for sepsis and that a level <0.5 ng/
mL is safe to stop antibiotics in septic ICU patients, there
is a persistent “gray area” from 0.5 to 1.9 ng/mL. Most
patients with SIRS have levels of 0.3–0.8 ng/mL, which
occupies some of this range. For now, these levels can only
represent worsening or resolution of an inflammatory or
septic process, depending upon which way the trend
moves. Thus, the trends are very important and will need
to be followed as the patient worsens or improves.
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and clinical judgment is still primary in deciding upon
initiation and termination of antibiotics. However, there
is now substantial evidence that procalcitonin can suc-
cessfully be used to guide antibiotic therapy and adds
tremendous benefit in limiting the excessive use of anti-
biotics. This biomarker is much more physiologically
reliable as an objective marker of ongoing infection, and
its use is justified by prospective randomized data. A
procalcitonin-based algorithm to terminate antibiotics
should be more widely accepted and is superior to courses
of antibiotics based upon a pre-determined number of
days.
Conclusions
The following conclusions use the Oxford Centre for
Evidence-Based Medicine 2009 levels of evidence:
1. In septic ICU patients, a clinically recovered
physiological situation and a serum procalcitonin level
less than 0.5 ng/mL appear to be an acceptable and
safe time to discontinue antibiotics. (Level 1b evidence)
2. The use of procalcitonin to decide when to stop
antibiotics based upon a level less than 0.5 ng/mL in
patients with pulmonary infections and/or sepsis has
been shown to reduce total antibiotic use and decrease
the duration of antibiotics. (Level 1b evidence)
3. An appropriate clinical situation and a procalcitonin
level above 2 ng/mL are diagnostic of sepsis with a
high sensitivity and specificity, and antibiotic therapy
should be started immediately. (Level 2a evidence)
4. A patient with a systemic inflammatory response and a
procalcitonin level less than 0.5 ng/mL is very unlikely
to have an infectious etiology of the SIRS response, and
antibiotics can be withheld, although the procalcitonin
level should be trended. (Level 2a evidence)
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